Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

2,185

 

EUR

 

-10,63 %

Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

5.091 følger denne virksomhed
Sammenligne
-10,63%
-13,98%
+7,37%
-13,29%
+40,42%
-37,21%
-33,18%
-29,52%
-37,21%

Faron Pharmaceuticals is a medical technology company. The company conducts research and development of therapeutic solutions used for the treatment of immune diseases and various organ damage. The largest operations are in North America and Europe, with hospitals and research institutes as the dominant customer base. In addition to the main business, various value-added services are offered. The head office is located in Turku.

Læs mere
Markedsværdi
228,61 mio. EUR
Aktieomsætning
1,12 mio. EUR
P/E (adj.) (24e)
-7,69
EV/EBIT (adj.) (24e)
-8,91
P/B (24e)
-22,37
EV/S (24e)
58.191,99
Udbytteafkast, % (24e)
-
Coverage
Anbefaling
Akkumulér
Kursmål
2.80 EUR
Opdateret
11.12.2024
Disclaimer
Antti Siltanen
Antti Siltanen

Analytiker

Latest research

Latest analysis report

Released: 11.12.2024

Latest extensive report

Released: 23.08.2022

Finanskalender
27.2
2025

Årsrapport '24

21.3
2025

Generalforsamling '25

27.8
2025

Delårsrapport Q2'25

Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper
Analyse af
Antti Siltanen

Faron: Towards final read-out in March

Faron reported more detailed interim results of the BEXMAB study at the annual meeting of the American Society of Hematology (ASH). The company is on track for the important final read-out in March, as tolerability and overall response rate have remained at good levels.

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.